(Q33382011)

26 July 2017

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors (English)

1 reference

26 July 2017

phase I clinical trial

0 references

1 reference

Sharon L Sanborn

1

1 reference

26 July 2017

Joseph Gibbons

2

1 reference

26 July 2017

Smitha Krishnamurthi

3

1 reference

26 July 2017

Joanna M Brell

4

1 reference

26 July 2017

Afshin Dowlati

5

1 reference

26 July 2017

Joseph A Bokar

6

1 reference

26 July 2017

Charles Nock

7

1 reference

26 July 2017

Nancy Horvath

8

1 reference

26 July 2017

Jacob Bako

9

1 reference

26 July 2017

Scot C Remick

10

1 reference

26 July 2017

Matthew M Cooney

11

1 reference

26 July 2017

15 November 2008

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

27

1 reference

26 July 2017

453-460

1 reference

26 July 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-008-9200-x

26 July 2017

0 references

cites work

Tumor angiogenesis: therapeutic implications

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-008-9200-X

Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma

21 January 2018

1 reference

12 December 2020

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

1 reference

12 December 2020

Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors

1 reference

12 December 2020

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

12 December 2020

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

1 reference

12 December 2020

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease

1 reference

12 December 2020

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

1 reference

12 December 2020

Antiangiogenesis for cancer therapy

1 reference

12 December 2020

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts

1 reference

12 December 2020

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

12 December 2020

Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.

1 reference

12 December 2020

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

12 December 2020

Tumor angiogenesis: past, present and the near future

1 reference

12 December 2020

Antiangiogenic therapy for cancer: current and emerging concepts

1 reference

12 December 2020

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide

1 reference

12 December 2020

A cancer therapy resistant to resistance

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

12 December 2020

Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors

1 reference

12 December 2020

Lenalidomide--the phoenix rises.

1 reference

12 December 2020

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

1 reference

12 December 2020

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies

1 reference

12 December 2020

New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy

1 reference

12 December 2020

Clinical implications of antiangiogenic therapies.

1 reference

12 December 2020

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

1 reference

12 December 2020

Mechanisms and future directions for angiogenesis-based cancer therapies

1 reference

12 December 2020

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

12 December 2020

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

1 reference

12 December 2020

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

12 December 2020

Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.

1 reference

12 December 2020

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

12 December 2020

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

1 reference

12 December 2020

Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles

1 reference

12 December 2020

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study

1 reference

12 December 2020

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

1 reference

12 December 2020

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

12 December 2020

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

1 reference

12 December 2020

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

1 reference

12 December 2020

The microtubule-affecting drug paclitaxel has antiangiogenic activity

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

10.1007/S10637-008-9200-X

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference